Esperion Therapeutics Company Profile (NASDAQ:ESPR)

About Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics logoEsperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ESPR
  • CUSIP: N/A
  • Web: www.esperion.com
Capitalization:
  • Market Cap: $749.76 million
  • Outstanding Shares: 22,590,000
Average Prices:
  • 50 Day Moving Avg: $36.39
  • 200 Day Moving Avg: $23.37
  • 52 Week Range: $9.40 - $48.21
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.61
  • P/E Growth: 0.97
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $8.52 per share
  • Price / Book: 3.90
Profitability:
  • EBIDTA: ($101,960,000.00)
  • Return on Equity: -21.76%
  • Return on Assets: -21.07%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 26.16%
  • Quick Ratio: 26.16%
Misc:
  • Average Volume: 2.03 million shs.
  • Beta: 2.1
  • Short Ratio: 3.17
 

Frequently Asked Questions for Esperion Therapeutics (NASDAQ:ESPR)

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics Inc (NASDAQ:ESPR) released its quarterly earnings results on Monday, May, 1st. The company reported ($1.80) earnings per share for the quarter, missing analysts' consensus estimates of ($1.44) by $0.36. During the same period last year, the business earned ($0.65) EPS. View Esperion Therapeutics' Earnings History.

Where is Esperion Therapeutics' stock going? Where will Esperion Therapeutics' stock price be in 2017?

11 brokers have issued 12 month price targets for Esperion Therapeutics' shares. Their forecasts range from $12.50 to $67.00. On average, they anticipate Esperion Therapeutics' share price to reach $36.86 in the next year. View Analyst Ratings for Esperion Therapeutics.

What are analysts saying about Esperion Therapeutics stock?

Here are some recent quotes from research analysts about Esperion Therapeutics stock:

  • 1. According to Zacks Investment Research, "Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. " (5/9/2017)
  • 2. Needham & Company LLC analysts commented, "The FDA has agreed that the Phase III CLEAR LDL program of bempedoic acid is sufficient to support approval. This resolves a long standing issue for ESPR shares regarding the ability to get their drug approved without a completed CVOT. This regulatory confirmation comes on the heals of the positive FOURIER outcomes data for Repatha and the genetic validation of the target for bempedoic acid which was presented yesterday at the American College for Cardiology (ACC). As a result of this trifecta of positive news we are increasing our price target on ESPR to $58 from $25. We once again model US approval based on CLEAR LDL in 2020." (3/20/2017)

Are investors shorting Esperion Therapeutics?

Esperion Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totalling 4,768,401 shares, an increase of 19.6% from the March 15th total of 3,985,852 shares. Based on an average daily volume of 6,734,352 shares, the short-interest ratio is presently 0.7 days.

Who are some of Esperion Therapeutics' key competitors?

Who owns Esperion Therapeutics stock?

Esperion Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BOXER CAPITAL, LLC (6.80%), ALTA PARTNERS VIII, L.P. (6.50%), BB Biotech AG (6.24%), FMR LLC (5.80%), Boxer Capital LLC (5.64%) and Credit Suisse AG (3.89%). Company insiders that own Esperion Therapeutics stock include Dov A Md Goldstein, Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani and Timothy M Mayleben. View Institutional Ownership Trends for Esperion Therapeutics.

Who sold Esperion Therapeutics stock? Who is selling Esperion Therapeutics stock?

Esperion Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Aisling Capital LLC, Bank of America Corp DE, Martingale Asset Management L P, JPMorgan Chase & Co., Cim Investment Mangement Inc., Bellevue Group AG, Keybank National Association OH and Oxford Asset Management. View Insider Buying and Selling for Esperion Therapeutics.

Who bought Esperion Therapeutics stock? Who is buying Esperion Therapeutics stock?

Esperion Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Boxer Capital LLC, RA Capital Management LLC, Pinnacle Associates Ltd., FMR LLC, Aviva Holdings Ltd., UBS Asset Management Americas Inc., Credit Suisse AG and State Street Corp. Company insiders that have bought Esperion Therapeutics stock in the last two years include Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani and Timothy M Mayleben. View Insider Buying and Selling for Esperion Therapeutics.

How do I buy Esperion Therapeutics stock?

Shares of Esperion Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Esperion Therapeutics stock cost?

One share of Esperion Therapeutics stock can currently be purchased for approximately $33.19.

Analyst Ratings

Consensus Ratings for Esperion Therapeutics (NASDAQ:ESPR) (?)
Ratings Breakdown: 6 Hold Ratings, 4 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.55)
Consensus Price Target: $36.86 (11.07% upside)

Analysts' Ratings History for Esperion Therapeutics (NASDAQ:ESPR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/20/2017JPMorgan Chase & Co.Reiterated RatingHold$22.00 -> $50.00MediumView Rating Details
3/20/2017Citigroup IncSet Price TargetBuy$39.00MediumView Rating Details
3/20/2017Royal Bank of CanadaReiterated RatingHold$45.00HighView Rating Details
3/20/2017Needham & Company LLCBoost Price TargetStrong-Buy -> Strong-Buy$25.00 -> $58.00HighView Rating Details
3/20/2017Credit Suisse Group AGUpgradeUnderperform -> Neutral$29.00HighView Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/15/2016Stifel NicolausReiterated RatingBuy$64.00 -> $30.00N/AView Rating Details
10/15/2016Chardan CapitalReiterated RatingNeutral$12.50N/AView Rating Details
8/31/2016Barclays PLCSet Price TargetHold$13.00N/AView Rating Details
7/5/2016WallachBeth CapitalDowngradeBuy -> Hold$35.00N/AView Rating Details
6/29/2016Lake Street CapitalLower Price TargetBuy$80.00 -> $27.00N/AView Rating Details
11/6/2015Bank of America CorpReiterated RatingBuy$65.00N/AView Rating Details
8/17/2015FIXReiterated RatingaddN/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Esperion Therapeutics (NASDAQ:ESPR)
Earnings by Quarter for Esperion Therapeutics (NASDAQ:ESPR)
Earnings History by Quarter for Esperion Therapeutics (NASDAQ:ESPR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2017Q1 2017($1.44)($1.80)ViewN/AView Earnings Details
2/22/201712/31/2016($1.24)($1.29)ViewN/AView Earnings Details
11/3/2016Q3($0.82)($0.77)ViewN/AView Earnings Details
8/4/2016Q2($0.78)($0.62)ViewN/AView Earnings Details
5/4/2016Q116($0.74)($0.65)ViewN/AView Earnings Details
2/25/2016Q4($0.61)($0.58)ViewN/AView Earnings Details
11/5/2015Q3($0.60)($0.57)ViewN/AView Earnings Details
8/6/2015Q215($0.58)($0.55)ViewN/AView Earnings Details
5/7/2015Q115($0.54)($0.56)ViewN/AView Earnings Details
3/5/2015Q4 2014($0.54)($0.49)ViewN/AView Earnings Details
8/12/2014Q214($0.55)($0.60)ViewN/AView Earnings Details
5/12/2014Q1 2014($0.62)($0.51)ViewN/AView Earnings Details
3/5/2014($0.50)($0.63)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Esperion Therapeutics (NASDAQ:ESPR)
Current Year EPS Consensus Estimate: $-6.69 EPS
Next Year EPS Consensus Estimate: $-4.36 EPS

Dividends

Dividend History for Esperion Therapeutics (NASDAQ:ESPR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Esperion Therapeutics (NASDAQ:ESPR)
Insider Ownership Percentage: 35.40%
Institutional Ownership Percentage: 64.65%
Insider Trades by Quarter for Esperion Therapeutics (NASDAQ:ESPR)
Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)
Insider Trades by Quarter for Esperion Therapeutics (NASDAQ:ESPR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/22/2017Dov A Md GoldsteinDirectorSell800,000$41.66$33,328,000.00View SEC Filing  
3/21/2017Gilbert S OmennDirectorBuy1,000$42.26$42,260.00View SEC Filing  
11/1/2016Narendra D LalwaniCOOBuy5,000$9.93$49,650.00View SEC Filing  
7/6/2016Mark E McgovernDirectorBuy5,000$10.00$50,000.00View SEC Filing  
5/4/2016Timothy M MaylebenCEOBuy7,000$14.85$103,950.00View SEC Filing  
3/1/2016Gilbert S OmennDirectorBuy5,000$15.28$76,400.00View SEC Filing  
1/27/2016Timothy M MaylebenCEOBuy3,600$15.88$57,168.00View SEC Filing  
1/15/2016Timothy M MaylebenCEOBuy7,200$14.08$101,376.00View SEC Filing  
4/24/2015Dov A Md GoldsteinDirectorSell217,469$108.22$23,534,495.18View SEC Filing  
11/18/2014Patrick G EnrightDirectorSell487,130$32.78$15,968,121.40View SEC Filing  
10/21/2014Parters Vii L P DomainMajor ShareholderBuy500,000$20.00$10,000,000.00View SEC Filing  
10/7/2014Longitude Capital Partners, LlMajor ShareholderSell11,927$30.04$358,287.08View SEC Filing  
7/1/2013Brian H DoveyMajor ShareholderBuy285,714$14.00$3,999,996.00View SEC Filing  
7/1/2013Daniel JanneyDirectorBuy235,714$14.00$3,299,996.00View SEC Filing  
7/1/2013Roger S NewtonChairmanBuy42,346$14.00$592,844.00View SEC Filing  
7/1/2013Timothy M MaylebenCEOBuy5,000$14.00$70,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Esperion Therapeutics (NASDAQ:ESPR)
Latest Headlines for Esperion Therapeutics (NASDAQ:ESPR)
Source:
DateHeadline
americanbankingnews.com logoEsperion Therapeutics Inc (ESPR) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 22 at 2:17 PM
finance.yahoo.com logoEsperion Provides Update on Common Stock Trading Activity
finance.yahoo.com - May 22 at 11:42 AM
seekingalpha.com logoEsperion Therapeutics: Up, Up, And Away? - Seeking Alpha
seekingalpha.com - May 19 at 9:51 PM
finance.yahoo.com logoEsperion to Participate in Fireside Chat at the UBS Global Healthcare Conference
finance.yahoo.com - May 19 at 4:49 PM
finance.yahoo.com logoEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - May 19 at 5:19 AM
finance.yahoo.com logoEsperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2017 Healthcare Conference
finance.yahoo.com - May 12 at 5:34 PM
americanbankingnews.com logoEsperion Therapeutics Inc (ESPR) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - May 9 at 7:30 PM
finance.yahoo.com logoToday's Research Report on Biotech Stocks to Watch: Immunomedics and Esperion Therapeutics
finance.yahoo.com - May 8 at 9:08 AM
finance.yahoo.com logoWhy Esperion Therapeutics Shares Were Flat In April
finance.yahoo.com - May 6 at 10:37 AM
finance.yahoo.com logoEsperion Therapeutics reports 1Q loss
finance.yahoo.com - May 5 at 5:16 PM
finance.yahoo.com logoEsperion Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 4 at 5:11 PM
americanbankingnews.com logoZacks: Analysts Anticipate Esperion Therapeutics Inc (ESPR) Will Announce Earnings of -$1.48 Per Share
www.americanbankingnews.com - May 4 at 1:26 PM
americanbankingnews.com logoEsperion Therapeutics (ESPR) Receiving Somewhat Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - May 2 at 9:52 AM
americanbankingnews.com logoEsperion Therapeutics Inc (ESPR) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 1 at 9:30 PM
americanbankingnews.com logoSomewhat Favorable Press Coverage Extremely Likely to Impact Esperion Therapeutics (ESPR) Stock Price
www.americanbankingnews.com - April 29 at 12:53 PM
americanbankingnews.com logoEsperion Therapeutics Inc (ESPR) to Release Earnings on Monday
www.americanbankingnews.com - April 29 at 7:09 AM
americanbankingnews.com logoEsperion Therapeutics (ESPR) Receives Daily Coverage Optimism Score of 0.20
www.americanbankingnews.com - April 27 at 1:11 AM
americanbankingnews.com logoEsperion Therapeutics Inc (ESPR) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 25 at 2:50 PM
americanbankingnews.com logoEsperion Therapeutics (ESPR) Earns News Impact Rating of 0.15
www.americanbankingnews.com - April 23 at 10:02 PM
americanbankingnews.com logoEsperion Therapeutics (ESPR) Getting Somewhat Favorable Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 20 at 9:47 PM
finance.yahoo.com logo3 Clinical-Stage Biotech Stocks That Could Be About to Strike It Rich
finance.yahoo.com - April 19 at 12:13 PM
americanbankingnews.com logoSomewhat Positive News Coverage Very Likely to Affect Esperion Therapeutics (ESPR) Share Price
www.americanbankingnews.com - April 17 at 10:16 PM
americanbankingnews.com logoRoyal Bank of Canada Reaffirms Hold Rating for Esperion Therapeutics Inc (ESPR)
www.americanbankingnews.com - April 16 at 12:52 PM
americanbankingnews.com logoSomewhat Favorable Press Coverage Extremely Likely to Impact Esperion Therapeutics (ESPR) Share Price
www.americanbankingnews.com - April 14 at 9:09 PM
americanbankingnews.com logoZacks: Analysts Expect Esperion Therapeutics Inc (ESPR) to Announce -$1.48 EPS
www.americanbankingnews.com - April 13 at 11:22 AM
benzinga.com logoCardiovascular Players Could Be Eyeing Esperion
www.benzinga.com - April 11 at 4:53 PM
investopedia.com logoRegeneron's Evinacumab Gets Breakthrough Designation (REGN)
www.investopedia.com - April 7 at 9:42 AM
fool.com logoThe 3 Best Cholesterol Drug Stocks to Buy in 2017
www.fool.com - March 30 at 5:30 PM
finance.yahoo.com logoEsperion to Participate in Fireside Chat at the 16th Annual Needham Healthcare Conference
finance.yahoo.com - March 28 at 4:44 PM
americanbankingnews.com logoJPMorgan Chase & Co. Increases Esperion Therapeutics Inc (ESPR) Price Target to $50.00
www.americanbankingnews.com - March 27 at 10:25 AM
americanbankingnews.com logoCitigroup Inc Raises Esperion Therapeutics Inc (ESPR) Price Target to $77.00
www.americanbankingnews.com - March 25 at 9:33 AM
americanbankingnews.com logoDov A. Md Goldstein Sells 800,000 Shares of Esperion Therapeutics Inc (ESPR) Stock
www.americanbankingnews.com - March 23 at 7:35 PM
americanbankingnews.com logoInsider Buying: Esperion Therapeutics Inc (ESPR) Director Purchases 1,000 Shares of Stock
www.americanbankingnews.com - March 22 at 10:52 AM
americanbankingnews.com logoEsperion Therapeutics Inc (ESPR) Given a $39.00 Price Target by Citigroup Inc Analysts
www.americanbankingnews.com - March 21 at 4:25 PM
americanbankingnews.com logoEsperion Therapeutics' (ESPR) Hold Rating Reaffirmed at JPMorgan Chase & Co.
www.americanbankingnews.com - March 21 at 3:03 PM
americanbankingnews.com logoEsperion Therapeutics Inc (ESPR) Price Target Raised to $50.00 at JPMorgan Chase & Co.
www.americanbankingnews.com - March 21 at 11:34 AM
investopedia.com logoEsperion Gets FDA Nod for LDL-C Program (ESPR)
www.investopedia.com - March 20 at 7:34 PM
us.rd.yahoo.com logoEsperion Therapeutics upgraded by Credit Suisse
us.rd.yahoo.com - March 20 at 7:34 PM
marketwatch.com logoEsperion Therapeutics stock surges 52% after it says the FDA gave its drug program positive feedback
us.rd.yahoo.com - March 20 at 7:34 PM
us.rd.yahoo.com logoEsperion Gets FDA Nod for Cholesterol Drug Program
us.rd.yahoo.com - March 20 at 7:34 PM
fool.com logoHere's What Pushed Esperion Therapeutics Inc Stock Higher Today
www.fool.com - March 20 at 7:34 PM
cnbc.com logoAfter-hours buzz: ESPR, NKTR, MMSI & more
www.cnbc.com - March 20 at 7:34 PM
americanbankingnews.com logoRoyal Bank of Canada Reiterates Hold Rating for Esperion Therapeutics Inc (ESPR)
www.americanbankingnews.com - March 20 at 4:24 PM
americanbankingnews.com logoEsperion Therapeutics Inc (ESPR) PT Raised to $58.00
www.americanbankingnews.com - March 20 at 1:43 PM
americanbankingnews.com logoEsperion Therapeutics Inc (ESPR) Raised to "Neutral" at Credit Suisse Group AG
www.americanbankingnews.com - March 20 at 12:16 PM
fool.com logoHere's Why Amgen, The Medicines Company, and Esperion Therapeutics Are All Tanking Today - Motley Fool
www.fool.com - March 18 at 10:16 AM
benzinga.com logoEsperion Falls Victim To Amgen's Poor Repatha Results
www.benzinga.com - March 17 at 10:24 PM
us.rd.yahoo.com logoAmgen Tanks On Heart Study; Shares Of Other Drugmakers Tumble
us.rd.yahoo.com - March 17 at 5:23 PM
americanbankingnews.com logoEsperion Therapeutics Inc (ESPR) PT Set at $39.00 by Citigroup Inc
www.americanbankingnews.com - March 13 at 4:28 PM
nasdaq.com logoEsperion Therapeutics (ESPR) Jumps: Stock Moves Up 8.6% - Nasdaq
www.nasdaq.com - March 10 at 6:09 PM

Social

Chart

Esperion Therapeutics (ESPR) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff